| Ira N Targoff, MD | |
|
825 Ne 10th St, Oupb 2300, Oklahoma City, OK 73104-5417 | |
| (405) 271-8478 | |
| (405) 271-4230 |
| Full Name | Ira N Targoff |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 49 Years |
| Location | 825 Ne 10th St, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215906920 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| O U Medical Center | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ou Health Partners Inc | 5991105876 | 779 |
News Archive
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Adding another reason for doctors to avoid the overuse of antibiotics, new research shows that a reduction in the variety of microbes in the gut interferes with the immune system's ability to fight off disease.
The American Academy of Orthopaedic Surgeons has approved and released an evidence-based clinical practice guideline on "The Treatment of Glenohumeral Joint Osteoarthritis." This major joint in the shoulder - the ball and socket joint - is sometimes affected by osteoarthritis, causing pain, loss of function, and reduced quality of life.
Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.
› Verified 4 days ago
| Entity Name | Board Of Regents Of The University Of Oklahoma - Ou Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801869250 PECOS PAC ID: 2860304334 Enrollment ID: O20031103000607 |
News Archive
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Adding another reason for doctors to avoid the overuse of antibiotics, new research shows that a reduction in the variety of microbes in the gut interferes with the immune system's ability to fight off disease.
The American Academy of Orthopaedic Surgeons has approved and released an evidence-based clinical practice guideline on "The Treatment of Glenohumeral Joint Osteoarthritis." This major joint in the shoulder - the ball and socket joint - is sometimes affected by osteoarthritis, causing pain, loss of function, and reduced quality of life.
Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.
› Verified 4 days ago
| Entity Name | Ou Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528642642 PECOS PAC ID: 5991105876 Enrollment ID: O20210615000618 |
News Archive
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Adding another reason for doctors to avoid the overuse of antibiotics, new research shows that a reduction in the variety of microbes in the gut interferes with the immune system's ability to fight off disease.
The American Academy of Orthopaedic Surgeons has approved and released an evidence-based clinical practice guideline on "The Treatment of Glenohumeral Joint Osteoarthritis." This major joint in the shoulder - the ball and socket joint - is sometimes affected by osteoarthritis, causing pain, loss of function, and reduced quality of life.
Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ira N Targoff, MD 1122 Ne 13th St, Ori 236, Oklahoma City, OK 73117-1039 Ph: (405) 271-1515 | Ira N Targoff, MD 825 Ne 10th St, Oupb 2300, Oklahoma City, OK 73104-5417 Ph: (405) 271-8478 |
News Archive
Cutaneous application of nanoparticles may offer a new means of delivering drugs to treat erectile dysfunction (ED), according to findings presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA).
Adding another reason for doctors to avoid the overuse of antibiotics, new research shows that a reduction in the variety of microbes in the gut interferes with the immune system's ability to fight off disease.
The American Academy of Orthopaedic Surgeons has approved and released an evidence-based clinical practice guideline on "The Treatment of Glenohumeral Joint Osteoarthritis." This major joint in the shoulder - the ball and socket joint - is sometimes affected by osteoarthritis, causing pain, loss of function, and reduced quality of life.
Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.
› Verified 4 days ago
Evelyn Lorents, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 920 Sl Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Patrick Bronson Reeves, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3366 Nw Expressway Ste 550, Oklahoma City, OK 73112 Phone: 405-942-5442 Fax: 405-942-6448 | |
Dr. Jake Lee Evans, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Aat 6300, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Metri Haddaden, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young Blvd # 8425, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 410-554-2184 | |
Divya Sharma Divyadarshini, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Dr. Philip Barton Miner, Jr., M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1000 N Lincoln Blvd, Suite 210, Oklahoma City, OK 73104 Phone: 405-271-4644 Fax: 405-271-3296 | |
Gary Lee Worcester, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Ste 400, Oklahoma City, OK 73112 Phone: 405-947-3341 |